"Assessment of Risk" for non-chemo hazardous drugs

PLEASE NOTE:   Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP). 

Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jgold@ismp.org

10 posts / 0 new
Last post
Karen Thompson
Karen Thompson's picture
Last seen: 4 months 1 week ago
Joined: 05/03/2009 - 02:30
"Assessment of Risk" for non-chemo hazardous drugs

I just finished attending the USP 800 presentation at the ASHP Summer mtg. It was a great review of chemo handling, but I wanted to hear more about handling non-antineoplastic hazardous drugs. Guidelines for handling chemo are pretty straightforward and staff are on board. It's the non-chemo (spironolactone, carbamazepine, oxytocin) that is causing confusion and frustration. The speakers said to do an "Assessment of Risk", then you can handle non-chemo differently...I am not a toxicologist and do not feel that I have the expertise (or liability insurance!) to make that kind of call. How are others handling non-chemo hazardous drugs? Has anyone done the "assessment of risk" that is mentioned in USP 800?

These are the scenarios I have trouble with:
Do you mix an oxytocin drip in a chemo hood?
Do RNs wear PPE and dispose of them in a chemo waste bin when administering phenytoin?
Do RNs need to dispose of diapers in a chemo waste bin if their patient is on carbamazepine?

Any help/thoughts are much appreciated!